secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001157523-23-001312
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise reports Q2 2023 net loss $21.5M; positive ARCH 12-month data for EDG-5506
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $310M as of June 30, 2023.
- R&D expenses $19.6M, G&A $5.8M; net loss $0.34 per share.
- ARCH study: CK reduced 37% (p=0.001), fast skeletal troponin I reduced 79% (p<0.0001) at 12 months.
- GRAND CANYON pivotal cohort for Becker expected to start enrollment in 2H 2023; ~120 patients.
- Phase 1 trial of EDG-7500 for HCM expected to start in 2H 2023, subject to IND clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000115752323001312/0001157523-23-001312-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000115752323001312/a53523949.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-001312

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer